Abrostep MB Tablet contains Acebrophylline 200mg, a bronchodilator and mucolytic agent, Montelukast 10mg, a leukotriene receptor antagonist, and Bilastine 20mg, a non-sedating antihistamine. This combination provides comprehensive relief in respiratory and allergic conditions, targeting inflammation, bronchoconstriction, and histamine-mediated symptoms.
Clinically, it is indicated for asthma, chronic bronchitis, allergic rhinitis, and seasonal or perennial allergies. Acebrophylline improves airway clearance and reduces bronchospasm, Montelukast prevents leukotriene-mediated inflammation, and Bilastine alleviates allergic symptoms such as sneezing, itching, and nasal congestion.
The tablet formulation ensures precise dosing, consistent bioavailability, and synergistic therapeutic effect, making it suitable for pulmonology clinics, ENT and allergy centers, hospitals, and specialty pharmacies. Regular use under medical supervision supports symptom control and improved respiratory function.
Abrostep MB Tablet helps in reducing airway inflammation, relieving bronchial constriction, controlling allergic responses, and improving patient quality of life. Its proven efficacy and safety make it a trusted multi-action therapy for respiratory and allergic disorders.